New Synexus Board Gears up for Expansion Through Organic Growth and Acquisition

  • Several of the new board members have senior management experience with pharma and CROs
  • Synexus will broaden the number of therapy areas it offers to pharma and CROs

CHORLEY, England--Following the completion of the management buyout of Synexus the new board confirms its intention to expand the company's footprint through organic growth and acquisition.

Synexus, already the world's largest multi-national company dedicated to the recruitment and running of clinical trials at its own research centers, intends to become a major player in the US, continue to expand its existing network of sites in Europe and Africa and develop a presence in Asia and South America.

The new board members of Synexus are: Chairman Charles Woler and non-executives Benjamin Harrild, Hywel Evans, Ged Gould and Simon Braham. CEO of Synexus, Christophe Berthoux, and Financial Director of Synexus, Paul Chambers, will remain on the board.

Chairman Charles Woler has spent the last 30 years in the healthcare industry, both in large multinational pharmaceutical companies, SMEs and lately in smaller, earlier stage companies – positions included Chairman and CEO of Roche France, Chairman of SmithKline Beecham's European pharmaceutical business, and CEO of Cadus Pharmaceuticals.

Benjamin Harrild is the head of UK for the direct lending team of BlueBay Asset Management LLP, and was part of BlueBay's direct lending business from its inception in 2011.

Hywel Evans has a wide experience in pharma and the CRO sector. His experience includes being Managing Director of Novo Nordisk UK, Managing Director of Takeda Pharmaceuticals UK, and after joining Quintiles he rose to become President of Europe. He is also Chairman of Western Sussex Hospitals NHS Trust.

Ged Gould is Director and Office Head of LDC Manchester – part of the Lloyds Group - and has over 20 years of experience from the advisory arena, private equity, as well as being the Finance Director of two private equity backed businesses.

Simon Braham is the Investment Director at LDC Manchester and has over 17 years' experience in advisory, banking, restructuring and private equity.

Professor Trevor Jones, CBE, will continue to chair the Synexus Scientific Advisory Board.

Christophe Berthoux CEO of Synexus commented: "We are delighted with the strength of our new board and the expertise they bring. We are confident they will help us deliver the ambitious plans we have to expand not only geographically with new research centers but also in broadening the number of therapy areas we offer to our pharma and CRO clients."

Since 2007, Synexus has expanded its international network of dedicated research centers across eight countries. Recent expansion has included new site openings in the UK, Germany, Romania, Poland, Bulgaria and South Africa.

The management buyout from Lyceum Capital last year was carried out with the backing of LDC who is the leading private equity company in the UK mid-market and part of the Lloyds Banking Group.


For Synexus:
Vane Percy & Roberts
Simon Vane Percy
(T) +44 (0)1737 821890
(e) [email protected]